Cardiac Monitoring Standards for People on Antipsychotics

Cardiac monitoring for people on antipsychotics is designed to detect risks such as QT prolongation before they lead to dangerous arrhythmias. Yet established standards are applied inconsistently, leaving gaps between known risk and actual protection. Closing those gaps requires more than additional ECGs. It requires clear clinical responsibility, action on abnormal results, and support that makes repeated monitoring accessible to people with serious mental illness.

Why people on antipsychotics face elevated cardiac risk

Sudden cardiac death is one of the serious hazards facing people who take antipsychotics. For people with serious mental illness, or SMI, that hazard sits within a broader pattern of premature death and elevated cardiovascular risk. Monitoring responds to a documented biological risk. The drugs can affect the heart’s electrical activity, while the people taking them may already have conditions that increase their vulnerability.

The mechanism begins with the IKr potassium channel. Antipsychotics can block this channel, delaying ventricular repolarization, the electrical recovery of the heart’s lower chambers. This lengthens the QT interval, which reflects the combined electrical activity of ventricular muscle cells. The delay can create conditions for torsades de pointes, or TdP, a polymorphic ventricular tachycardia that can cause sudden cardiac death. When QTc, the interval corrected for heart rate, exceeds 500 msec, the risk of TdP rises sharply.

Low-potency first-generation antipsychotics, including chlorpromazine and thioridazine, have elevated TdP risk, while clozapine is also associated with myocarditis and cardiomyopathy. QT prolongation is therefore not the whole picture. Female sex, advanced age, preexisting arrhythmias, electrolyte abnormalities, renal or hepatic dysfunction, and cardiovascular history can compound the medication-related risk. Antipsychotic polypharmacy adds another concern, particularly when several agents prolong QT.

A single threshold helps flag a high-risk reading, but clinical judgment also depends on what else is happening with the patient. Monitoring standards attempt to turn that combination into a structured response.

What the established monitoring standards actually specify

Baseline ECG measurement anchors most QTc monitoring approaches. It establishes the reference against which subsequent readings can be interpreted, while follow-up depends on the patient’s risk and the treatment being used. The standards differ in their lower QTc thresholds, the circumstances that trigger testing, and the frequency of repeat ECGs.

Nottinghamshire APC guideline V2.3, reviewed June 2025, says a baseline ECG should be considered for all patients. It specifically recommends one in circumstances including a family history of long QTc or physiological risk factors, and recommends annual ECGs when any risk factors are present. Other protocols specify baseline ECGs at initiation and annual repeats when QTc remains below 470 msec in women or 440 msec in men. Between those thresholds and 500 msec, dose reduction or a switch may be considered. A baseline QTc above 500 msec is a reason not to initiate the antipsychotic under that protocol.

The American Heart Association uses different lower thresholds, above 460 msec in women and above 450 msec in men. The Association of Medicine and Psychiatry consensus algorithm identifies high risk above 500 msec and intermediate risk at 450–499 msec in males and above 470 through 499 msec in females. Those differences should remain visible in practice. Although guidance converges on the high-risk cutoff, a lower reading can be classified differently depending on the standard used. Bazett’s formula provides a method of correcting the measured QT interval for heart rate.

Risk tools add structure beyond the ECG reading. MedSafety Scan provides a QTc prolongation risk score for non-ICU patients, while the Tisdale score is used for ICU patients. Credible Meds classifies drugs by known, possible, or conditional risk of TdP. These tools address related but distinct questions. A drug’s risk classification does not replace assessment of the person receiving it.

NSW Health’s clozapine guideline addresses a separate concern, early detection of myocarditis. It requires baseline testing before treatment begins. Relevant symptoms, an abnormally increased heart rate, or raised CRP of 50–100 mg/L trigger daily high-sensitivity troponin and CRP measurements and daily ECGs. This is not simply another QTc threshold. It reflects clozapine’s additional cardiac hazards.

One important area remains less clearly specified. There are no universally accepted guidelines defining how often ECG monitoring should occur after a QTc-prolonging antipsychotic is administered on an inpatient medicine unit. Broader cardiovascular assessment also varies by tool. QRISK3, used in England, includes SMI and antipsychotic use in its 10-year risk calculation, whereas SCORE2, used in the Netherlands, does not.

How far actual practice falls short of those standards

A 2025 audit at Salford CAMHS found that only about a third of children and young people received baseline ECGs. The audit identified this as non-compliance with NICE guidelines. A UK general hospital study published in June 2025 found baseline ECG compliance below half, with repeat ECGs after dose escalation performed for only a small minority. The shortfall affected people in different age groups and care settings. It was not confined to one point in treatment.

A two-year audit cycle in 2024–2025 checked whether patients taking atypical antipsychotics had their cardiovascular risk factors monitored. More patients received monitoring after steps were taken to improve it, but many still went without it. A primary care retrospective study found a different weakness in how surveillance was allocated. Patients taking high-metabolic-risk antipsychotics, such as olanzapine, and those receiving antipsychotic polypharmacy did not receive more frequent monitoring.

Harb et al.’s 2024 study, Pharmacist Reported Protocols for QTc Monitoring of Psychiatric Medications, found formal QTc monitoring protocols at only 11.4% of surveyed institutions. Roughly a third had only an informal process, and practice varied between providers, settings, and institutions. Fewer than half of pharmacist respondents said pharmacists at their institution could order an ECG. Even someone trained to spot medication-related risk might not be allowed to order the test needed to measure it.

Baseline ECG completion, cardiovascular risk factor assessment, and institutional protocols each describe a different part of the process. Their findings nevertheless point in the same direction.

Why the gaps persist: systemic barriers, not just individual oversight

Cardiac monitoring spans psychiatry, primary care, and internal medicine, without a single specialty consistently owning the whole process. A prescription may originate in one setting while cardiac follow-up depends on another. That division creates a coordination problem. People with SMI may receive care in settings that lack either the infrastructure or the mandate to complete the required monitoring.

When no one is clearly in charge, monitoring can depend on each clinician’s judgment. The informal arrangements documented in the pharmacist study help explain why practice varies, although they do not establish the cause of every missed ECG. Limited staff awareness and absent standard operating procedures have also been proposed as explanations in audit literature. Such explanations should be distinguished from causes directly investigated by an audit.

Poverty, unstable housing, and medication side effects can make appointments difficult to keep for people with SMI. These are practical barriers. Describing interrupted monitoring only as patient non-adherence obscures the social and logistical needs that help explain it. Calling for repeated testing does little on its own to meet those needs.

The same fragmentation affects prevention beyond ECG monitoring. Statins are equally effective in people with SMI as in the general population, yet remain underused in this group. The Fixed Dose Intervention Trial of New England Enhancing Survival in SMI, known as FITNESS, is testing a structural response. It compares usual treatment with free, fixed-dose generic statins and angiotensin drugs given to patients within mental health clinics. The trial tests whether moving prevention into that setting increases the number of people receiving it compared with referral elsewhere.

What the consequences of the monitoring gap look like for patients

A missed ECG can mean a missed opportunity to intervene. An elevated QTc is actionable because clinicians can consider reducing the dose, changing the agent, correcting electrolyte abnormalities, or reviewing polypharmacy. Without a baseline reading, there is no starting point to compare later measurements against. A missed test leaves a safeguard intended to identify avoidable risk absent.

The primary care study found that monitoring did not change in response to abnormal results, suggesting a gap in acting on findings as well as obtaining them. The distinction is consequential for patients. Detecting a problem provides protection only when it leads to an appropriate clinical response. Otherwise, a completed test can coexist with unresolved risk.

People with SMI face an explicit inequity: they have elevated baseline cardiovascular risk, yet cardiovascular risk management is not being applied at equivalent rates to care that is routine in general practice. Those facing the widest monitoring gaps are also those with the least access to alternative safety nets. Poverty and unstable housing can keep people from planned care and make it harder to find care elsewhere.

The 2025 ESC Clinical Consensus Statement on mental health affirms that regular cardiovascular risk assessment is essential for people with SMI regardless of other factors. Even completed assessments may understate risk if the tool omits SMI and antipsychotic use, as SCORE2 does. This introduces another possible blind spot. Fair care requires both access to the same test and an assessment that takes account of the risks people have.

What closing the gap requires in practice

Health systems should put formal QTc monitoring protocols in place and make clear who does what in psychiatric and medical settings. Harb et al. suggest authorizing pharmacists to order ECGs as a concrete advance. Embedding risk tools into prescribing workflows would also make them less dependent on optional consultation.

Local protocols can make clear what to do while work toward wider agreement continues. Inpatient medicine services can define post-initiation ECG arrangements rather than leave that acknowledged guidance gap unresolved. For broader cardiovascular assessment, systems should use QRISK3 or an equivalent that accounts for SMI and antipsychotic use. Care integration offers another route forward. Providing cardiovascular prevention within mental health clinics, as the FITNESS trial is testing, can help keep care from breaking down when people are referred elsewhere.

Clinical organization cannot remove every obstacle to attendance. Community-based support is also needed to address transportation, housing, appointment navigation, and medication adherence. Peer support from people who have themselves navigated serious mental illness can build trust and help sustain engagement across repeated care contacts. This support addresses the access conditions under which clinical monitoring can actually occur.

Is better monitoring enough to reduce the wider cardiovascular burden? Some experts argue that persistent excess mortality also calls for more aggressive cardioprotective treatment alongside greater ECG adherence. That question remains connected to, but distinct from, the implementation gap. Current shortfalls make it premature to treat inconsistent monitoring as a test of what consistently applied standards can achieve.

People with SMI deserve the same cardiac vigilance as anyone else. Achieving it requires both clinical infrastructure that detects and responds to risk and community infrastructure that makes that protection accessible.